JNJ-88545223

Phase 2Small molecule

Johnson & Johnson

JNJ-88545223 is one of 50 small molecule programs targeting Psoriatic Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psoriatic ArthritisActive, not recruiting

Arthritis, PsoriaticRecruiting

Psoriatic ArthritisPhase 2

Active, not recruiting

Arthritis, PsoriaticPhase 2

Recruiting

Competition

Competitive Landscape

114 competitors in Psoriatic Arthritis

#DrugCompanyPhaseTrials

Bimzelx

UCB

Phase 3

9 2

Skyrizi

AbbVie

Phase 3

8 3

Jyseleca

Gilead

Phase 3

4 4

Taxol

Teva

Phase 3

1 5

Keytruda

Merck & Co.

Phase 3

1 6

Icotyde

Johnson & Johnson

Phase 3

1 7

Xeljanz

PPrism Pharmaceuticals

Phase 3

8 8

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Arthritis, Psoriatic

NCT07321873

Clinical

Trials by Indication[1]

Arthritis, Psoriatic1 trial

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 For the Treatment of Participants With Active Psoriatic Arthritis

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT07321873·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JNJ-88545223. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-88545223 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-88545223. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

JNJ-88545223

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Arthritis, Psoriatic1 trial

References

Drug Info

Quick Facts

Related News